Publications

Selected Publications

Scheidegger M. Comparative phenomenology and neurobiology of meditative and psychedelic states of consciousness: Implications for psychedelic-assisted therapy. In: Grob CS, Grigsby J (eds.): Handbook of Medical Hallucinogens. New York: Guilford Publications, 2020 (in press).

Scheidegger M. Psychedelic medicines and their role in shifting the paradigm from pharmacological substitution towards transformation-based psychiatry. In: Labate, Beatriz C & Cavnar, C (eds.): Ayahuasca Healing and Science. Cham, Switzerland: Springer, 2020 (in press).

Smigielski L, Kometer M, Scheidegger M, Krähenmann R, Huber T, Vollenweider FX. Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat. Sci Rep. 2019 Oct 24;9(1):14914. doi: 10.1038/s41598-019-50612-3.

Smigielski L, Scheidegger M, Kometer M, Vollenweider FX. Psilocybin-assisted mindfulness training modulates self-consciousness and brain default mode network connectivity with lasting effects. Neuroimage. 2019 Aug 1;196:207-215. doi:10.1016/j.neuroimage.2019.04.009.

Gärtner M, Aust S, Bajbouj M, Fan Y, Wingenfeld K, Otte C, Heuser-Collier I, Böker H, Hättenschwiler J, Seifritz E, Grimm S, Scheidegger M. Functional connectivity between prefrontal cortex and subgenual cingulate predicts antidepressant effects of ketamine. Eur Neuropsychopharmacol. 2019 Apr;29(4):501-508. doi: 10.1016/j.euroneuro.2019.02.008.

Jungaberle H, Thal S, Zeuch A, Rougemont-Bücking A, von Heyden M, Aicher H, Scheidegger M. Positive psychology in the investigation of psychedelics and entactogens: A critical review. Neuropharmacology. 2018 Nov;142:179-199. doi:10.1016/j.neuropharm.2018.06.034.

Scheidegger M, Henning A, Walter M, Lehmann M, Kraehenmann R, Boeker H, Seifritz E, Grimm S. Ketamine administration reduces amygdalo-hippocampal reactivity to emotional stimulation. Hum Brain Mapp. 2016 May;37(5):1941-52. doi:10.1002/hbm.23148.

Scheidegger M, Henning A, Walter M, Boeker H, Weigand A, Seifritz E, Grimm S. Effects of ketamine on cognition-emotion interaction in the brain. Neuroimage. 2016 Jan 1;124(Pt A):8-15. doi: 10.1016/j.neuroimage.2015.08.070.

Kraehenmann R, Preller KH, Scheidegger M, Pokorny T, Bosch OG, Seifritz E, Vollenweider FX. Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers. Biol Psychiatry. 2015 Oct 15;78(8):572-81. doi: 10.1016/j.biopsych.2014.04.010.

Scheidegger M, Walter M, Lehmann M, Metzger C, Grimm S, Boeker H, Boesiger P, Henning A, Seifritz E. Ketamine decreases resting state functional network connectivity in healthy subjects: implications for antidepressant drug action. PLoS One. 2012;7(9):e44799. doi: 10.1371/journal.pone.0044799.

Complete publication list